This report provides a comprehensive analysis of the global tumor NGS detection market, which is projected to experience significant growth through 2032. Driven by the need to identify clinically treatable genetic variants, the market is segmented by type, application, and geography, covering areas such as companion diagnostics and early cancer screening. The study evaluates key players, competitive strategies, and regional trends across the Americas, APAC, and Europe to highlight emerging opportunities and the industry's future trajectory.

Executive Overview

Market Projections

The global Tumor NGS Detection market size is predicted to grow from US$ 2711 million in 2025 to US$ 7697 million in 2032, representing a compound annual growth rate (CAGR) of 16.4% from 2026 to 2032.

Regional Market Trends

• United States: The market for Tumor NGS Detection is estimated to experience significant growth from 2025 through 2032.
• China: The market for Tumor NGS Detection is estimated to undergo expansion between 2025 and 2032.
• Europe: The market for Tumor NGS Detection is estimated to increase over the period from 2025 to 2032.

Core Purpose

The primary objective of Next-Generation Sequencing (NGS) is to discover clinically treatable genetic variants and to guide patient treatment.

Report Scope and Methodology

Research Content

LPI (LP Information)' newest research report, the “Tumor NGS Detection Industry Forecast,” reviews total world Tumor NGS Detection sales in 2025 based on past sales data. The report provides a comprehensive analysis by region and market sector of projected Tumor NGS Detection sales for the period from 2026 through 2032. This detailed analysis of the world Tumor NGS Detection industry is presented in US$ millions, with sales broken down by region, market sector, and sub-sector.

Analytical Depth

This Insight Report provides a comprehensive analysis of the global Tumor NGS Detection landscape, highlighting key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

The report also analyzes the strategies of leading global companies, focusing on their Tumor NGS Detection portfolios and capabilities, market entry strategies, market positions, and geographic footprints to better understand their unique positions in an accelerating global market.

Market Drivers and Forecasting

The report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor NGS Detection. It breaks down the forecast by type, application, geography, and market size to highlight emerging pockets of opportunity. Utilizing a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory of the global Tumor NGS Detection market.

Market Opportunities

The report presents a comprehensive overview, market shares, and growth opportunities of the Tumor NGS Detection market categorized by product type, application, key players, and key regions and countries.

Market Segmentation

By Type

• Medical Equipment
• Consumables

By Application

• Companion Diagnostics
• Early Cancer Screening
• Drug Discovery
• Other

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Players and Market Position

Global key Tumor NGS Detection players include Agilent, Thermo Fisher Scientific, BGI Group, Roche Foundation Medicine, and Sinopharm Group, among others. In 2025, the global two largest companies occupied a significant portion of the market share.

Profiled Companies

The following companies have been profiled based on inputs gathered from primary experts and an analysis of their coverage, product portfolio, and market penetration:

• Agilent
• Thermo Fisher Scientific
• BGI Group
• Roche Foundation Medicine
• Sinopharm Group
• Fosunpharma
• Novogene
• Geneseeq
• AmoyDx
• Burning Rock Medicine
• Perkin Elmer
• Qiagen NV
• Partek
• Illumina Inc.
• Pacific Biosciences of California Inc.
• Life Technologies Corporation
• GTH.O
• Paradigm Diagnostics
• Oxford Nanopore Technologies Ltd.
• Eurofins Scientific S.E.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Tumor NGS Detection Market Size (2021-2032)

    • 2.1.2 Tumor NGS Detection Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Tumor NGS Detection by Country/Region (2021, 2025 & 2032)

  • 2.2 Tumor NGS Detection Segment by Type

    • 2.2.1 Medical Equipment

    • 2.2.2 Consumables

    • 2.2.3 Tumor NGS Detection Market Size by Type

      • 2.2.3.1 Tumor NGS Detection Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.3.2 Global Tumor NGS Detection Market Size Market Share by Type (2021-2026)

  • 2.3 Tumor NGS Detection Segment by Application

    • 2.3.1 Companion Diagnostics

    • 2.3.2 Early Cancer Screening

    • 2.3.3 Drug Discovery

    • 2.3.4 Other

    • 2.3.5 Tumor NGS Detection Market Size by Application

      • 2.3.5.1 Tumor NGS Detection Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.5.2 Global Tumor NGS Detection Market Size Market Share by Application (2021-2026)

• 3 Tumor NGS Detection Market Size by Player

  • 3.1 Tumor NGS Detection Market Size Market Share by Player

    • 3.1.1 Global Tumor NGS Detection Revenue by Player (2021-2026)

    • 3.1.2 Global Tumor NGS Detection Revenue Market Share by Player (2021-2026)

  • 3.2 Global Tumor NGS Detection Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Tumor NGS Detection by Region

  • 4.1 Tumor NGS Detection Market Size by Region (2021-2026)

  • 4.2 Global Tumor NGS Detection Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Tumor NGS Detection Market Size Growth (2021-2026)

  • 4.4 APAC Tumor NGS Detection Market Size Growth (2021-2026)

  • 4.5 Europe Tumor NGS Detection Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Tumor NGS Detection Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Tumor NGS Detection Market Size by Country (2021-2026)

  • 5.2 Americas Tumor NGS Detection Market Size by Type (2021-2026)

  • 5.3 Americas Tumor NGS Detection Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Tumor NGS Detection Market Size by Region (2021-2026)

  • 6.2 APAC Tumor NGS Detection Market Size by Type (2021-2026)

  • 6.3 APAC Tumor NGS Detection Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Tumor NGS Detection Market Size by Country (2021-2026)

  • 7.2 Europe Tumor NGS Detection Market Size by Type (2021-2026)

  • 7.3 Europe Tumor NGS Detection Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Tumor NGS Detection by Region (2021-2026)

  • 8.2 Middle East & Africa Tumor NGS Detection Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Tumor NGS Detection Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Tumor NGS Detection Market Forecast

  • 10.1 Global Tumor NGS Detection Forecast by Region (2027-2032)

    • 10.1.1 Global Tumor NGS Detection Forecast by Region (2027-2032)

    • 10.1.2 Americas Tumor NGS Detection Forecast

    • 10.1.3 APAC Tumor NGS Detection Forecast

    • 10.1.4 Europe Tumor NGS Detection Forecast

    • 10.1.5 Middle East & Africa Tumor NGS Detection Forecast

  • 10.2 Americas Tumor NGS Detection Forecast by Country (2027-2032)

    • 10.2.1 United States Market Tumor NGS Detection Forecast

    • 10.2.2 Canada Market Tumor NGS Detection Forecast

    • 10.2.3 Mexico Market Tumor NGS Detection Forecast

    • 10.2.4 Brazil Market Tumor NGS Detection Forecast

  • 10.3 APAC Tumor NGS Detection Forecast by Region (2027-2032)

    • 10.3.1 China Tumor NGS Detection Market Forecast

    • 10.3.2 Japan Market Tumor NGS Detection Forecast

    • 10.3.3 Korea Market Tumor NGS Detection Forecast

    • 10.3.4 Southeast Asia Market Tumor NGS Detection Forecast

    • 10.3.5 India Market Tumor NGS Detection Forecast

    • 10.3.6 Australia Market Tumor NGS Detection Forecast

  • 10.4 Europe Tumor NGS Detection Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Tumor NGS Detection Forecast

    • 10.4.2 France Market Tumor NGS Detection Forecast

    • 10.4.3 UK Market Tumor NGS Detection Forecast

    • 10.4.4 Italy Market Tumor NGS Detection Forecast

    • 10.4.5 Russia Market Tumor NGS Detection Forecast

  • 10.5 Middle East & Africa Tumor NGS Detection Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Tumor NGS Detection Forecast

    • 10.5.2 South Africa Market Tumor NGS Detection Forecast

    • 10.5.3 Israel Market Tumor NGS Detection Forecast

    • 10.5.4 Turkey Market Tumor NGS Detection Forecast

  • 10.6 Global Tumor NGS Detection Forecast by Type (2027-2032)

  • 10.7 Global Tumor NGS Detection Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Tumor NGS Detection Forecast

• 11 Key Players Analysis

  • 11.1 Agilent

    • 11.1.1 Agilent Company Information

    • 11.1.2 Agilent Tumor NGS Detection Product Offered

    • 11.1.3 Agilent Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Agilent Main Business Overview

    • 11.1.5 Agilent Latest Developments

  • 11.2 Thermo Fisher Scientific

    • 11.2.1 Thermo Fisher Scientific Company Information

    • 11.2.2 Thermo Fisher Scientific Tumor NGS Detection Product Offered

    • 11.2.3 Thermo Fisher Scientific Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Thermo Fisher Scientific Main Business Overview

    • 11.2.5 Thermo Fisher Scientific Latest Developments

  • 11.3 BGI Group

    • 11.3.1 BGI Group Company Information

    • 11.3.2 BGI Group Tumor NGS Detection Product Offered

    • 11.3.3 BGI Group Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 BGI Group Main Business Overview

    • 11.3.5 BGI Group Latest Developments

  • 11.4 Roche Foundation Medicine

    • 11.4.1 Roche Foundation Medicine Company Information

    • 11.4.2 Roche Foundation Medicine Tumor NGS Detection Product Offered

    • 11.4.3 Roche Foundation Medicine Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Roche Foundation Medicine Main Business Overview

    • 11.4.5 Roche Foundation Medicine Latest Developments

  • 11.5 Sinopharm Group

    • 11.5.1 Sinopharm Group Company Information

    • 11.5.2 Sinopharm Group Tumor NGS Detection Product Offered

    • 11.5.3 Sinopharm Group Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Sinopharm Group Main Business Overview

    • 11.5.5 Sinopharm Group Latest Developments

  • 11.6 Fosunpharma

    • 11.6.1 Fosunpharma Company Information

    • 11.6.2 Fosunpharma Tumor NGS Detection Product Offered

    • 11.6.3 Fosunpharma Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Fosunpharma Main Business Overview

    • 11.6.5 Fosunpharma Latest Developments

  • 11.7 Novogene

    • 11.7.1 Novogene Company Information

    • 11.7.2 Novogene Tumor NGS Detection Product Offered

    • 11.7.3 Novogene Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Novogene Main Business Overview

    • 11.7.5 Novogene Latest Developments

  • 11.8 Geneseeq

    • 11.8.1 Geneseeq Company Information

    • 11.8.2 Geneseeq Tumor NGS Detection Product Offered

    • 11.8.3 Geneseeq Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Geneseeq Main Business Overview

    • 11.8.5 Geneseeq Latest Developments

  • 11.9 AmoyDx

    • 11.9.1 AmoyDx Company Information

    • 11.9.2 AmoyDx Tumor NGS Detection Product Offered

    • 11.9.3 AmoyDx Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 AmoyDx Main Business Overview

    • 11.9.5 AmoyDx Latest Developments

  • 11.10 Burning Rock Medicine

    • 11.10.1 Burning Rock Medicine Company Information

    • 11.10.2 Burning Rock Medicine Tumor NGS Detection Product Offered

    • 11.10.3 Burning Rock Medicine Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Burning Rock Medicine Main Business Overview

    • 11.10.5 Burning Rock Medicine Latest Developments

  • 11.11 Perkin Elmer

    • 11.11.1 Perkin Elmer Company Information

    • 11.11.2 Perkin Elmer Tumor NGS Detection Product Offered

    • 11.11.3 Perkin Elmer Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Perkin Elmer Main Business Overview

    • 11.11.5 Perkin Elmer Latest Developments

  • 11.12 Qiagen NV

    • 11.12.1 Qiagen NV Company Information

    • 11.12.2 Qiagen NV Tumor NGS Detection Product Offered

    • 11.12.3 Qiagen NV Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 Qiagen NV Main Business Overview

    • 11.12.5 Qiagen NV Latest Developments

  • 11.13 Partek

    • 11.13.1 Partek Company Information

    • 11.13.2 Partek Tumor NGS Detection Product Offered

    • 11.13.3 Partek Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 Partek Main Business Overview

    • 11.13.5 Partek Latest Developments

  • 11.14 Illumina Inc.

    • 11.14.1 Illumina Inc. Company Information

    • 11.14.2 Illumina Inc. Tumor NGS Detection Product Offered

    • 11.14.3 Illumina Inc. Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 Illumina Inc. Main Business Overview

    • 11.14.5 Illumina Inc. Latest Developments

  • 11.15 Pacific Biosciences of California Inc.

    • 11.15.1 Pacific Biosciences of California Inc. Company Information

    • 11.15.2 Pacific Biosciences of California Inc. Tumor NGS Detection Product Offered

    • 11.15.3 Pacific Biosciences of California Inc. Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 Pacific Biosciences of California Inc. Main Business Overview

    • 11.15.5 Pacific Biosciences of California Inc. Latest Developments

  • 11.16 Life Technologies Corporation

    • 11.16.1 Life Technologies Corporation Company Information

    • 11.16.2 Life Technologies Corporation Tumor NGS Detection Product Offered

    • 11.16.3 Life Technologies Corporation Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.16.4 Life Technologies Corporation Main Business Overview

    • 11.16.5 Life Technologies Corporation Latest Developments

  • 11.17 GTH.O

    • 11.17.1 GTH.O Company Information

    • 11.17.2 GTH.O Tumor NGS Detection Product Offered

    • 11.17.3 GTH.O Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.17.4 GTH.O Main Business Overview

    • 11.17.5 GTH.O Latest Developments

  • 11.18 Paradigm Diagnostics

    • 11.18.1 Paradigm Diagnostics Company Information

    • 11.18.2 Paradigm Diagnostics Tumor NGS Detection Product Offered

    • 11.18.3 Paradigm Diagnostics Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.18.4 Paradigm Diagnostics Main Business Overview

    • 11.18.5 Paradigm Diagnostics Latest Developments

  • 11.19 Oxford Nanopore Technologies Ltd.

    • 11.19.1 Oxford Nanopore Technologies Ltd. Company Information

    • 11.19.2 Oxford Nanopore Technologies Ltd. Tumor NGS Detection Product Offered

    • 11.19.3 Oxford Nanopore Technologies Ltd. Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.19.4 Oxford Nanopore Technologies Ltd. Main Business Overview

    • 11.19.5 Oxford Nanopore Technologies Ltd. Latest Developments

  • 11.20 Eurofins Scientific S.E.

    • 11.20.1 Eurofins Scientific S.E. Company Information

    • 11.20.2 Eurofins Scientific S.E. Tumor NGS Detection Product Offered

    • 11.20.3 Eurofins Scientific S.E. Tumor NGS Detection Revenue, Gross Margin and Market Share (2021-2026)

    • 11.20.4 Eurofins Scientific S.E. Main Business Overview

    • 11.20.5 Eurofins Scientific S.E. Latest Developments

• 12 Research Findings and Conclusion